Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: A propensity score-matched analysis

Katsunori Tatsugami, Mototsugu Oya, Koki Kabu, Hideyuki Akaza

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years with advanced RCC. Methods: Data were extracted from <75-year-old and ≥75-year-old patient groups, matching those demographics considered to affect prognosis. Differences in patients' characteristics, dose modification, adverse events, tumour response, progression-free survival, and renal function (glomerular filtration) were evaluated between the groups. Results: From 2536 and 703 patients aged <75 and ≥75 years, respectively, 397 pairs were matched. Median daily dose was higher and duration of treatment longer in patients <75 years; however, progression-free survival and tumour response were similar in both age groups. Incidence of all adverse events was not significantly different between groups. The proportion of patients discontinuing treatment was higher in patients ≥75 years, but there was no significant difference between groups in the number patients discontinuing due to adverse events. Conclusions: For patients aged ≥75 years, sorafenib treatment had minimal additional negative impact compared to younger patients and showed similar efficacy and safety without reducing renal function.

Original languageEnglish
Pages (from-to)241-247
Number of pages7
JournalBritish journal of cancer
Volume119
Issue number2
DOIs
Publication statusPublished - Jul 17 2018

Fingerprint

Propensity Score
Kidney Neoplasms
Safety
Renal Cell Carcinoma
Disease-Free Survival
sorafenib
Kidney
Therapeutics
Protein-Tyrosine Kinases
Neoplasms
Age Groups

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older : A propensity score-matched analysis. / Tatsugami, Katsunori; Oya, Mototsugu; Kabu, Koki; Akaza, Hideyuki.

In: British journal of cancer, Vol. 119, No. 2, 17.07.2018, p. 241-247.

Research output: Contribution to journalArticle

@article{205f9acc35304b6f825871201b2c53a0,
title = "Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: A propensity score-matched analysis",
abstract = "Background: The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years with advanced RCC. Methods: Data were extracted from <75-year-old and ≥75-year-old patient groups, matching those demographics considered to affect prognosis. Differences in patients' characteristics, dose modification, adverse events, tumour response, progression-free survival, and renal function (glomerular filtration) were evaluated between the groups. Results: From 2536 and 703 patients aged <75 and ≥75 years, respectively, 397 pairs were matched. Median daily dose was higher and duration of treatment longer in patients <75 years; however, progression-free survival and tumour response were similar in both age groups. Incidence of all adverse events was not significantly different between groups. The proportion of patients discontinuing treatment was higher in patients ≥75 years, but there was no significant difference between groups in the number patients discontinuing due to adverse events. Conclusions: For patients aged ≥75 years, sorafenib treatment had minimal additional negative impact compared to younger patients and showed similar efficacy and safety without reducing renal function.",
author = "Katsunori Tatsugami and Mototsugu Oya and Koki Kabu and Hideyuki Akaza",
year = "2018",
month = "7",
day = "17",
doi = "10.1038/s41416-018-0129-3",
language = "English",
volume = "119",
pages = "241--247",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older

T2 - A propensity score-matched analysis

AU - Tatsugami, Katsunori

AU - Oya, Mototsugu

AU - Kabu, Koki

AU - Akaza, Hideyuki

PY - 2018/7/17

Y1 - 2018/7/17

N2 - Background: The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years with advanced RCC. Methods: Data were extracted from <75-year-old and ≥75-year-old patient groups, matching those demographics considered to affect prognosis. Differences in patients' characteristics, dose modification, adverse events, tumour response, progression-free survival, and renal function (glomerular filtration) were evaluated between the groups. Results: From 2536 and 703 patients aged <75 and ≥75 years, respectively, 397 pairs were matched. Median daily dose was higher and duration of treatment longer in patients <75 years; however, progression-free survival and tumour response were similar in both age groups. Incidence of all adverse events was not significantly different between groups. The proportion of patients discontinuing treatment was higher in patients ≥75 years, but there was no significant difference between groups in the number patients discontinuing due to adverse events. Conclusions: For patients aged ≥75 years, sorafenib treatment had minimal additional negative impact compared to younger patients and showed similar efficacy and safety without reducing renal function.

AB - Background: The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years with advanced RCC. Methods: Data were extracted from <75-year-old and ≥75-year-old patient groups, matching those demographics considered to affect prognosis. Differences in patients' characteristics, dose modification, adverse events, tumour response, progression-free survival, and renal function (glomerular filtration) were evaluated between the groups. Results: From 2536 and 703 patients aged <75 and ≥75 years, respectively, 397 pairs were matched. Median daily dose was higher and duration of treatment longer in patients <75 years; however, progression-free survival and tumour response were similar in both age groups. Incidence of all adverse events was not significantly different between groups. The proportion of patients discontinuing treatment was higher in patients ≥75 years, but there was no significant difference between groups in the number patients discontinuing due to adverse events. Conclusions: For patients aged ≥75 years, sorafenib treatment had minimal additional negative impact compared to younger patients and showed similar efficacy and safety without reducing renal function.

UR - http://www.scopus.com/inward/record.url?scp=85048329475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048329475&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0129-3

DO - 10.1038/s41416-018-0129-3

M3 - Article

C2 - 29891937

AN - SCOPUS:85048329475

VL - 119

SP - 241

EP - 247

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -